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New genetic marker for piperaquine resistance in Plasmodium 
falciparum
In the Greater Mekong subregion, Plasmodium falciparum 
resistance to artemisinins is increasingly compounded by 
concurrent resistance to partner drugs in combination 
therapies, which results in high treatment failure 
rates.1–6 Artemisinin combination therapies are ﬁ rst-
line drugs for the treatment of falciparum malaria in all 
endemic countries; new antimalarials will probably not 
be marketed within this decade.7 Clinical drug eﬃ  cacy 
studies are time and resource consuming and availability 
of molecular markers for drug resistance can facilitate 
near real-time monitoring, which is needed for guiding 
policy changes towards locally eﬀ ective combination 
therapies in the Greater Mekong subregion. Markers are 
available for artemisinin resistance (Kelch13 mutations8) 
and meﬂ oquine resistance (mdr1 ampliﬁ cation9). 
Markers for other artemisinin partner drugs used in 
the region, including lumefantrine, amodiaquine, and 
piperaquine, are less well deﬁ ned. 
In The Lancet Infectious Diseases, two separate studies 
by Benoit Witkowski and colleagues10 and Roberto 
Amato and colleagues11 both done in Cambodia, 
derived a much needed molecular marker for 
piperaquine resistance, a rapidly increasing problem 
in the Greater Mekong subregion: plasmepsin 2 and 
plasmepsin 3 gene ampliﬁ cations on chromosome 14. 
Amato and colleagues11 identiﬁ ed an additional marker, 
an exonuclease gene polymorphism on chromosome 
13 (exo-E415G), in strong linkage disequilibrium 
with plasmepsin 2–3 ampliﬁ cation. Slightly diﬀ erent 
approaches were used. Witkowski and colleagues10 did a 
genome-wide association study (GWAS) in a relatively 
small sample of 31 Cambodian parasite strains, using 
a previously validated piperaquine survival assay 
(PSA)6 to deﬁ ne the resistant in-vitro phenotype. The 
identiﬁ ed plasmepsin 2, as an amplicon reporter, was 
then assessed in 134 clinical ﬁ eld isolates, showing a 
much higher median ex-vivo PSA survival rate with two 
or more plasmepsin 2 copies compared with single copy 
(51·7% [IQR 29·7–75·1] vs 0·004% [IQR 0·003–0·39]). 
Additionally, in 725 Cambodian patients with un com-
plicated falciparum malaria treated between 2009 and 
2015 with dihydroartemisinin–piperaquine, multicopy 
plasmepsin 2 was associated with an adjusted hazard 
ratio for treatment failure at 42 days of 20·4 (95% CI 
9·1–45·5, p<0·0001). 
Amato and colleagues11 did GWAS on a larger sample 
of 297 Cambodian strains, allowing better correction 
for confounders such as parasite population structure; 
the piperaquine resistance phenotype was deﬁ ned by 
the 50% inhibitory concentration (IC50) of conventional 
in-vitro drug sensitivity testing. Samples were collected 
between 2010 and 2013 from three diﬀ erent provinces 
with marked diﬀ erent levels of artemisinin resistance 
and dihydroartemisinin–piperaquine failure. Both the 
exo-E415G and plasmepsin 2–3 markers were strongly 
associated with piperaquine IC50. In 133 patients 
treated with dihydroartemisinin–piperaquine and who 
had 63-day clinical eﬃ  cacy data available, adjusted 
treatment success rate with or without plasmepsin 2–3 
ampliﬁ cation was 0·41 (95% CI 0·28–0·53) and 0·95 
(0·87–0·98), respectively. Results for the exo-E415G 
marker were similar. 
The converging results of these studies make 
plasmepsin 2–3 ampliﬁ cation a robust marker for 
piperaquine resistance in the region. There is a sug-
gestion of a causal relationship, since both plasmepsins 
and 4-aminoquinolines (like piperaquine) aﬀ ect 
haemoglobin degradation and haem detoxiﬁ cation 
processes. P falciparum transfected with multicopy 
plasmepsin 2–3 will be an invaluable tool to explore 
underlying resistance mechanisms.
The studies contain a wealth of additional infor-
mation. There was a consistent absence of mdr1 
ampliﬁ cation in plasmepsin 2–3 ampliﬁ ed parasite 
strains. Although interrupted meﬂ oquine drug pressure 
could also have contributed, this ﬁ nding could imply 
that these markers represent counteracting resistance 
mechanisms. This possibility would make alternating 
meﬂ oquine and piperaquine as partner drug, or 
combining them in triple combinations (currently under 
trial), attractive treatment modalities. 
The geotemporal trends in molecular markers show 
that the sequence of events has been ﬁ rst arrival of 
artemisinin resistance followed by a sharp increase 
in piperaquine resistance. Resistance to short half-
life artemisinins after 3-day artemisinin combination 
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therapy regimens leads to a greater than 100 times 
larger residual parasite biomass exposed to the partner 
drug,12 which selects for partner drug resistance (as 
observed with meﬂ oquine on the Thai–Myanmar 
border).1 The pharmacokinetics of piperaquine shows 
an initial relatively rapid plasma clearance followed 
by a long terminal half-life (2–4 weeks),13 so that small 
increases in minimal parasitocidal concentrations 
will result in a much shorter period of time parasites 
are exposed to parasitocidal concentrations, further 
contributing to selection. Once resistance to both 
artemisinin combination therapy components appear, 
selection of multidrug resistant parasites will strongly 
amplify because of high treatment failure rates and 
higher gametocytaemia in recrudescent infections,14 
driving transmission to the Anopheles spp vector. 
Antimalarial drug resistance threatens to oﬀ set the 
impressive gains made over the past decade in reducing 
falciparum malaria transmission in the Greater Mekong 
subregion to the current historically low numbers. We 
have to eliminate falciparum malaria from the region 
now before it becomes close to untreatable. 
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